Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$29.54−1.08 (-3.53%)
Close on Nov 13, 2026Market cap $1.16BP/E –Yield –
Alto Neuroscience ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Alto Neuroscience's ebitda for the twelve months ending Jun 30, 2025 was -$69.60M. For fiscal 2024 it was -$68.11M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$68.11M | – |
| FY2023 | Dec 31, 2023 | -$37.44M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -$18.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.51M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.83M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.69M | – |
| Q2 FY2024 | Jun 30, 2024 | -$18.24M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.65M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.62M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.03M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.12M | – |
See a number that looks wrong?